» Articles » PMID: 23243180

Assessment of Population-based HIV RNA Levels in a Rural East African Setting Using a Fingerprick-based Blood Collection Method

Abstract

Background: Population-based human immunodeficiency virus type 1 (HIV-1) RNA levels (viral load [VL]) are proposed metrics for antiretroviral therapy (ART) program effectiveness. We estimated population-based HIV RNA levels using a fingerprick-based approach in a rural Ugandan community implementing rapid ART scale-up.

Methods: A fingerprick-based HIV RNA measurement technique was validated against standard phlebotomy. This technique was deployed during a 5-day community-wide health campaign in a 6300-person community. Assessments included rapid HIV antibody testing, VL, and CD4+ T-cell count via fingerprick. We estimated population HIV RNA levels and the prevalence of undetectable RNA, assessed predictors of VL via linear regression, and mapped RNA levels within community geographic units.

Results: During the community-wide health campaign, 179 of 2282 adults (7.8%) and 10 of 1826 children (0.5%) tested seropositive for HIV. Fingerprick VL was determined in 174 of 189 HIV-positive persons (92%). The mean log(VL) was 3.67 log (95% confidence interval [CI], 3.50-3.83 log copies/mL), median VL was 2720 copies/mL (interquartile range, <486-38 120 copies/mL), and arithmetic mean VL was 64 064 copies/mL. Overall, 64 of 174 of individuals had undetectable RNA (37% [95% CI, 30%-44%]), 24% had VL 486-10 000; 25% had VL 10 001-100 000; and 15% had VL>100 000 copies/mL. Among participants taking ART, 83% had undetectable VL.

Conclusions: We developed and implemented a fingerprick VL testing method and provide the first report of population HIV RNA levels in Africa. In a rural Ugandan community experiencing ART scale-up, we found evidence of population-level ART effectiveness, but found a substantial population to be viremic, in need of ART, and at risk for transmission.

Citing Articles

Adapt for Adolescents: Protocol for a sequential multiple assignment randomized trial to improve retention and viral suppression among adolescents and young adults living with HIV in Kenya.

Abuogi L, Kulzer J, Akama E, Odeny T, Eshun-Wilson I, Petersen M Contemp Clin Trials. 2023; 127:107123.

PMID: 36813086 PMC: 10075086. DOI: 10.1016/j.cct.2023.107123.


HIV stigma limits the effectiveness of PMTCT in Guinea: the ANRS 12344-DIAVINA study.

Breton G, Cisse M, Diallo O, Diallo N, Soumaoro S, Camara Y J Antimicrob Chemother. 2022; 77(11):3093-3101.

PMID: 36031792 PMC: 9616546. DOI: 10.1093/jac/dkac287.


Far from MCAR: Obtaining Population-level Estimates of HIV Viral Suppression.

Balzer L, Ayieko J, Kwarisiima D, Chamie G, Charlebois E, Schwab J Epidemiology. 2020; 31(5):620-627.

PMID: 32452912 PMC: 8105880. DOI: 10.1097/EDE.0000000000001215.


HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.

Havlir D, Balzer L, Charlebois E, Clark T, Kwarisiima D, Ayieko J N Engl J Med. 2019; 381(3):219-229.

PMID: 31314966 PMC: 6748325. DOI: 10.1056/NEJMoa1809866.


Progress toward UNAIDS 90-90-90 targets: A respondent-driven survey among female sex workers in Kampala, Uganda.

Doshi R, Sande E, Ogwal M, Kiyingi H, McIntyre A, Kusiima J PLoS One. 2018; 13(9):e0201352.

PMID: 30231030 PMC: 6145590. DOI: 10.1371/journal.pone.0201352.


References
1.
Montaner J, Lima V, Barrios R, Yip B, Wood E, Kerr T . Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010; 376(9740):532-9. PMC: 2996043. DOI: 10.1016/S0140-6736(10)60936-1. View

2.
Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, Hatzold K . Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune Defic Syndr. 2010; 55(1):1-7. DOI: 10.1097/QAI.0b013e3181e93071. View

3.
Chamie G, Kwarisiima D, Clark T, Kabami J, Jain V, Geng E . Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One. 2012; 7(8):e43400. PMC: 3423366. DOI: 10.1371/journal.pone.0043400. View

4.
Thompson M, Aberg J, Cahn P, Montaner J, Rizzardini G, Telenti A . Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304(3):321-33. DOI: 10.1001/jama.2010.1004. View

5.
Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. PMC: 3200068. DOI: 10.1056/NEJMoa1105243. View